The estimated Net Worth of Greg D Aunan is at least $1.24 millió dollars as of 15 May 2020. Greg Aunan owns over 32,459 units of Neogenomics stock worth over $1,239,185 and over the last 9 years Greg sold NEO stock worth over $0.
Greg has made over 8 trades of the Neogenomics stock since 2018, according to the Form 4 filled with the SEC. Most recently Greg exercised 32,459 units of NEO stock worth $626,459 on 15 May 2020.
The largest trade Greg's ever made was exercising 32,741 units of Neogenomics stock on 2 August 2019 worth over $588,356. On average, Greg trades about 4,147 units every 20 days since 2015. As of 15 May 2020 Greg still owns at least 75,977 units of Neogenomics stock.
You can see the complete history of Greg Aunan stock trades at the bottom of the page.
Greg's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van és Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: